John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital, Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Becker, Richard C., John H. Alexander, Christopher Dyke, Yao Huang, Henock Saint-Jacques, Vic Hasselblad, Robert A. Harrington, Edwin G. Bovill, and Edwin G. XaNADU-1B Investigators. “Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease..” Thromb Res 117, no. 4 (2006): 439–46. https://doi.org/10.1016/j.thromres.2005.03.017.

PMID
15882894
Full Text

Alexander, John H., Gail Hafley, Robert A. Harrington, Eric D. Peterson, T Bruce Ferguson, Todd J. Lorenz, Abhinav Goyal, et al. “Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial..” Jama 294, no. 19 (November 16, 2005): 2446–54. https://doi.org/10.1001/jama.294.19.2446.

PMID
16287955
Full Text

Halabi, Abdul R., John H. Alexander, Linda K. Shaw, Todd J. Lorenz, Lawrence Liao, David F. Kong, Carmelo A. Milano, Robert A. Harrington, and Peter K. Smith. “Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery..” Am J Cardiol 96, no. 9 (November 1, 2005): 1254–59. https://doi.org/10.1016/j.amjcard.2005.06.067.

PMID
16253593
Full Text

Alexander, John H., T Bruce Ferguson, Diane M. Joseph, Michael J. Mack, Randall K. Wolf, C Michael Gibson, Daniel Gennevois, et al. “The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics..” Am Heart J 150, no. 4 (October 2005): 643–49. https://doi.org/10.1016/j.ahj.2005.05.021.

PMID
16209958
Full Text

Mahaffey, Kenneth W., Matthew T. Roe, Rakhi Kilaru, John K. French, John H. Alexander, Lisa G. Berdan, Frans Van De Werf, et al. “Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes..” Am J Cardiol 95, no. 12 (June 15, 2005): 1404–8. https://doi.org/10.1016/j.amjcard.2005.02.005.

PMID
15950560
Full Text

Mehta, Rajendra H., Robert M. Califf, Jyotsna Garg, Karen S. Pieper, John H. Alexander, David J. Moliterno, Frans Van de Werf, et al. “Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy..” Am J Cardiol 95, no. 11 (June 1, 2005): 1371–75. https://doi.org/10.1016/j.amjcard.2005.01.087.

PMID
15904648
Full Text

Mehta, Rajendra H., John H. Alexander, Frans Van de Werf, Paul W. Armstrong, Karen S. Pieper, Jyotsna Garg, Robert M. Califf, and Christopher B. Granger. “Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes..” Jama 293, no. 14 (April 13, 2005): 1746–50. https://doi.org/10.1001/jama.293.14.1746.

PMID
15827313
Full Text

Meine, Trip J., Sana M. Al-Khatib, John H. Alexander, Christopher B. Granger, Harvey D. White, Rakhi Kilaru, Kathryn Williams, E Magnus Ohman, Eric Topol, and Robert M. Califf. “Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy..” Am Heart J 149, no. 4 (April 2005): 670–74. https://doi.org/10.1016/j.ahj.2004.07.035.

PMID
15990751
Full Text

Alexander, J. H., H. Yang, R. C. Becker, K. Kodama, S. Goodman, C. K. Dyke, N. S. Kleiman, et al. “First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial..” Journal of Thrombosis and Haemostasis : Jth 3, no. 3 (March 2005): 439–47. https://doi.org/10.1111/j.1538-7836.2004.01081.x.

PMID
15748230
Full Text

Borges-Neto, Salvador, Linda K. Shaw, Robert H. Tuttle, John H. Alexander, William T. Smith, Marianna Chambless, R Edward Coleman, Robert A. Harrington, and Robert M. Califf. “Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease..” Am J Cardiol 95, no. 2 (January 15, 2005): 182–88. https://doi.org/10.1016/j.amjcard.2004.09.004.

PMID
15642549
Full Text

Pages